167 related articles for article (PubMed ID: 11758760)
1. Influence of P-glycoprotein modulators on cardiac uptake, metabolism, and effects of idarubicin.
Kang W; Weiss M
Pharm Res; 2001 Nov; 18(11):1535-41. PubMed ID: 11758760
[TBL] [Abstract][Full Text] [Related]
2. Modeling the metabolism of idarubicin to idarubicinol in rat heart: effect of rutin and phenobarbital.
Kang W; Weiss M
Drug Metab Dispos; 2003 Apr; 31(4):462-8. PubMed ID: 12642473
[TBL] [Abstract][Full Text] [Related]
3. P-glycoprotein inhibitors enhance saturable uptake of idarubicin in rat heart: pharmacokinetic/pharmacodynamic modeling.
Weiss M; Kang W
J Pharmacol Exp Ther; 2002 Feb; 300(2):688-94. PubMed ID: 11805234
[TBL] [Abstract][Full Text] [Related]
4. Effects of idarubicin and idarubicinol on rat coronary resistance and vasoconstrictor responsiveness of isolated aorta and mesentery.
Weiss M; Giessler C; Kang W
Anticancer Drugs; 2006 Jan; 17(1):69-74. PubMed ID: 16317292
[TBL] [Abstract][Full Text] [Related]
5. Effect of PSC 833 on the cytotoxicity of idarubicin and idarubicinol in multidrug-resistant K562 cells.
Fukushima T; Yamashita T; Yoshio N; Misaki H; Yamauchi T; Imamura S; Urasaki Y; Ueda T
Leuk Res; 1999 Jan; 23(1):37-42. PubMed ID: 9933133
[TBL] [Abstract][Full Text] [Related]
6. Restoring uptake and retention of daunorubicin and idarubicin in P170-related multidrug resistance cells by low concentration D-verapamil, cyclosporin-A and SDZ PSC 833.
Michieli M; Damiani D; Michelutti A; Candoni A; Masolini P; Scaggiante B; Quadrifoglio F; Baccarani M
Haematologica; 1994; 79(6):500-7. PubMed ID: 7896208
[TBL] [Abstract][Full Text] [Related]
7. The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines with varying lipophilicity.
Mülder HS; Dekker H; Pinedo HM; Lankelma J
Biochem Pharmacol; 1995 Sep; 50(7):967-74. PubMed ID: 7575681
[TBL] [Abstract][Full Text] [Related]
8. Modulation of resistance to idarubicin by the cyclosporin PSC 833 (valspodar) in multidrug-resistant cells.
Lacayo NJ; Duran GE; Sikic BI
J Exp Ther Oncol; 2003; 3(3):127-35. PubMed ID: 14641819
[TBL] [Abstract][Full Text] [Related]
9. Partial inhibition of the P-glycoprotein-mediated transport of anthracyclines in viable resistant K562 cells after irradiation in the presence of a verapamil analogue.
Mankhetkorn S; Teodori E; Garnier-Suillerot A
Chem Biol Interact; 1999 Jul; 121(2):125-40. PubMed ID: 10418960
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of idarubicin in the isolated perfused rat lung: effect of cinchonine and rutin.
Kuhlmann O; Hofmann HS; Müller SP; Weiss M
Anticancer Drugs; 2003 Jul; 14(6):411-6. PubMed ID: 12853881
[TBL] [Abstract][Full Text] [Related]
11. Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines.
Roovers DJ; van Vliet M; Bloem AC; Lokhorst HM
Leuk Res; 1999 Jun; 23(6):539-48. PubMed ID: 10374847
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
Ross DD; Doyle LA; Yang W; Tong Y; Cornblatt B
Biochem Pharmacol; 1995 Nov; 50(10):1673-83. PubMed ID: 7503771
[TBL] [Abstract][Full Text] [Related]
13. Comparison of drug accumulation in P-glycoprotein-expressing and MRP-expressing human leukaemia cells.
Davey MW; Hargrave RM; Davey RA
Leuk Res; 1996 Aug; 20(8):657-64. PubMed ID: 8913319
[TBL] [Abstract][Full Text] [Related]
14. In vitro effect of multidrug resistance modifiers on idarubicinol efflux in blasts of acute myeloid leukemia.
Schröder JK; Kasimir-Bauer S; Seeber S; Scheulen ME
J Cancer Res Clin Oncol; 2000 Feb; 126(2):111-6. PubMed ID: 10664252
[TBL] [Abstract][Full Text] [Related]
15. Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in acute myeloid leukaemia.
Grey M; Borg AG; Wood P; Burgess R; Fisher A; Yin JA
Leuk Res; 1997 Sep; 21(9):867-74. PubMed ID: 9393602
[TBL] [Abstract][Full Text] [Related]
16. Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resistant LoVo cell lines.
Toffoli G; Simone F; Gigante M; Boiocchi M
Biochem Pharmacol; 1994 Nov; 48(10):1871-81. PubMed ID: 7986198
[TBL] [Abstract][Full Text] [Related]
17. Caffeine enhances myocardial uptake of idarubicin but reverses its negative inotropic effect.
Kang W; Weiss M
Naunyn Schmiedebergs Arch Pharmacol; 2003 Feb; 367(2):151-5. PubMed ID: 12595956
[TBL] [Abstract][Full Text] [Related]
18. Idarubicin DNA intercalation is reduced by MRP1 and not Pgp.
Smeets ME; Raymakers RA; Vierwinden G; Pennings AH; Boezeman J; Minderman H; de Witte TM
Leukemia; 1999 Sep; 13(9):1390-8. PubMed ID: 10482990
[TBL] [Abstract][Full Text] [Related]
19. Cellular pharmacology of idarubicinol in multidrug-resistant LoVo cell lines.
Toffoli G; Corona G; Simone F; Gigante M; De Angeli S; Boiocchi M
Int J Cancer; 1996 Jul; 67(1):129-37. PubMed ID: 8690513
[TBL] [Abstract][Full Text] [Related]
20. The ability of verapamil to restore intracellular accumulation of anthracyclines in multidrug resistant cells depends on the kinetics of their uptake.
Mankhetkorn S; Garnier-Suillerot A
Eur J Pharmacol; 1998 Feb; 343(2-3):313-21. PubMed ID: 9570481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
